796 related articles for article (PubMed ID: 27267625)
1. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
2. Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells.
Hossein-Nejad-Ariani H; Althagafi E; Kaur K
Sci Rep; 2019 Feb; 9(1):2723. PubMed ID: 30804365
[TBL] [Abstract][Full Text] [Related]
3. Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery.
Chen G; Wang Y; Xie R; Gong S
J Control Release; 2017 Aug; 259():105-114. PubMed ID: 28159516
[TBL] [Abstract][Full Text] [Related]
4. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
5. Quantum-Dot-Based Theranostic Micelles Conjugated with an Anti-EGFR Nanobody for Triple-Negative Breast Cancer Therapy.
Wang Y; Wang Y; Chen G; Li Y; Xu W; Gong S
ACS Appl Mater Interfaces; 2017 Sep; 9(36):30297-30305. PubMed ID: 28845963
[TBL] [Abstract][Full Text] [Related]
6. GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways.
Pi J; Jiang J; Cai H; Yang F; Jin H; Yang P; Cai J; Chen ZW
Drug Deliv; 2017 Nov; 24(1):1549-1564. PubMed ID: 29019267
[TBL] [Abstract][Full Text] [Related]
7. In vivo and ex vivo proofs of concept that cetuximab conjugated vitamin E TPGS micelles increases efficacy of delivered docetaxel against triple negative breast cancer.
Kutty RV; Chia SL; Setyawati MI; Muthu MS; Feng SS; Leong DT
Biomaterials; 2015 Sep; 63():58-69. PubMed ID: 26081868
[TBL] [Abstract][Full Text] [Related]
8. Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors.
Agnello L; Tortorella S; d'Argenio A; Carbone C; Camorani S; Locatelli E; Auletta L; Sorrentino D; Fedele M; Zannetti A; Franchini MC; Cerchia L
J Exp Clin Cancer Res; 2021 Jul; 40(1):239. PubMed ID: 34294133
[TBL] [Abstract][Full Text] [Related]
9. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
10. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
11. A novel redox/pH dual-responsive and hyaluronic acid-decorated multifunctional magnetic complex micelle for targeted gambogic acid delivery for the treatment of triple negative breast cancer.
Sang MM; Liu FL; Wang Y; Luo RJ; Huan XX; Han LF; Zhang ZT; Feng F; Qu W; Liu W; Zheng F
Drug Deliv; 2018 Nov; 25(1):1846-1857. PubMed ID: 30334478
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene nano-micelles effect on triple-negative breast cancer is mediated through estrogen receptor-β and epidermal growth factor receptor.
Greish K; Nehoff H; Bahman F; Pritchard T; Taurin S
J Drug Target; 2019 Sep; 27(8):903-916. PubMed ID: 30615483
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment.
Khondee S; Chittasupho C; Tima S; Anuchapreeda S
Curr Drug Deliv; 2018; 15(3):406-416. PubMed ID: 28707580
[TBL] [Abstract][Full Text] [Related]
14. Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
He X; Cai K; Zhang Y; Lu Y; Guo Q; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Li C; Sun T; Cheng J; Jiang C
ACS Appl Mater Interfaces; 2018 Nov; 10(46):39455-39467. PubMed ID: 30362704
[TBL] [Abstract][Full Text] [Related]
15. Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer.
He C; Cai P; Li J; Zhang T; Lin L; Abbasi AZ; Henderson JT; Rauth AM; Wu XY
J Control Release; 2017 Jan; 246():98-109. PubMed ID: 28017889
[TBL] [Abstract][Full Text] [Related]
16. EGFR-targeted poly(ethylene glycol)-distearoylphosphatidylethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation, characterization and in vitro evaluation.
Ren H; Gao C; Zhou L; Liu M; Xie C; Lu W
Drug Deliv; 2015; 22(6):785-94. PubMed ID: 24670093
[TBL] [Abstract][Full Text] [Related]
17. Nanosoldiers: A promising strategy to combat triple negative breast cancer.
Pawar A; Prabhu P
Biomed Pharmacother; 2019 Feb; 110():319-341. PubMed ID: 30529766
[TBL] [Abstract][Full Text] [Related]
18. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
[TBL] [Abstract][Full Text] [Related]
19. pH sensitive peptide functionalized nanoparticles for co-delivery of erlotinib and DAPT to restrict the progress of triple negative breast cancer.
Wan X; Liu C; Lin Y; Fu J; Lu G; Lu Z
Drug Deliv; 2019 Dec; 26(1):470-480. PubMed ID: 30957572
[TBL] [Abstract][Full Text] [Related]
20. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
